Studies on regulation of cell growth have mainly focused on the growth induction machinery and only recently have they dealt with the complex pathways involved in cell cycle exit. One of the reasons for this one-sided focus may have been the overriding interest in cancer research and tumor induction, with the hope of unraveling new growth induction mechanisms. In retrospect, however, the majority of the cells in animals, including those in humans, are growth arrested and do not divide. Cell turnover may be controlled by apoptosis, but the reversible or irreversible growth arrest of differentiated cells is almost complete in the nervous system and mitosis signals are rare in most other tissues and organs. The molecular machinery controlling the arrested stage may therefore be even more complex than the growth induction mechanisms. In accordance with this hypothesis is the observation that the few bacteria capable of reversible growth arrest, such as the spores in B. subtilis, govern the spore-forming events by at least 30 genes in its relatively small genome. A defect in any one of these genes leads to a defective pathway, with lower survival under stressed conditions. Likewise, defects in cell cycle exit mechanisms in mammalian cells may cause severe diseases. The best examples come from the growing cadre of so-called tumor suppressor genes, which obviously belong to a category of genes governing and policing the arrested stage. In this minireview I will attempt to identify recent progress in unraveling the control mechanisms involved in cell cycle exit and point to the diseases that might be associated with defective steps in these events.
Arrest at the Transcriptional Level
Every tissue appears to contain a cell type-specific configuration, allowing only genes relevant to that cell type to be transcribed. This noise reduction mechanism reduces the complexity of the substrate DNA available for the transcription machinery. On the other hand, when the chromatin has been opened, several specific activators and repressors may recognize the individual gene and its promoter in order to establish controlled expression of a desirable product. Therefore, in all eukaryotic cells we would expect at least a two-tiered level of transcriptional control-one at the chromatin level and one at the level of the opened genes.
Chromatin Silencing
Although it has been argued that chromatin silencing may limit genetic complexity (1), little is known about conserved mechanisms. In the yeast systems, on the other hand, both genes close to the telomere and those controlling mating type are regulated by silencing (2) (4) . Both genes seem to share sequences with known acetyltransferases from bacteria, Tetrahymena, and human cells. The human homologues include the HIV Tat-interacting protein 60 (TIP60) and MOZ, a gene fused to a transcriptional activator (CBP) in a subclass of acute myeloid leukemia patients characterized by the t(8,16) (pll;p13) translocation (5) . The CBP moiety has previously been identified as a transcriptional activator that can bind the CREB transcription factor (cyclic AMP element bin d.-ing) upon stimulation with cAMP, but it can also work as a coactivator for retinoic acid receptors. Another similar coactivator, or adaptor, as they have often been called (6) , namely p300, is very similar to CBP in mammalian cells. A domain has been identified in these proteins that is homologous to two yeast genes associated with chromatin that can bind histone acetylase activity. likewise, both p300 and CBP can associate with P/CAF, which carries histone acetylase activity, in human cells (7) . Thus, in both yeast and mammalian cells, histone acetylase can bind to proteins that recognize specific loci through associated transcriptional factors, leading to transactivation and histone acetylation. These adaptors can obviously bind not only to several transcription factors, such as CREB and Jun, but also to enzymes leading to opening of the chromatin through histone acetylation. Whether the acetylation causes transcriptional repression or activation depends on the transcription factors associated with the CBP or p300 and their DNA binding domain. Figure 1 shows schematically how p300/CBP can both activate or repress transcription depending on the factor associated with the adaptor. It is of considerable interest that defects in this system, as shown in Figure 2 , can be involved in tumorigenesis. Direct mutations in CBP are associated with a heritable developmental disorder involving increased incidence of some tumors, the Rubinstein-Taybi syndrome (8) . In other instances, a fusion protein made between a silencing acetylase (MOZ) and CBP leads to a specific class of acute myeloid leukemia. This may be caused by either a different specificity for the natural (P/CAF) and the fused acetylase or an irreversible acetylation function due to the tethered molecules. Proof of the reversibility of acetylase binding comes from the fact that viral oncogenes, such as EIA, can displace P/CAF from the CBP (7) .
A true silencing function in mammalian cells has recently been revealed during studies of the myc oncogene and its homologues in cell culture. The Myc proteins, for which humans carry at least three genes, are able to form sequencespecific heterodimers with the Max protein, which leads to transcriptional activation, cell proliferation, and blocking of terminal differentiation. A translocation between an immunoglobulin gene and a myc gene in Epstein-Barr virus (EBV)-induced lymphomas provided clues to the importance of the myc oncogene in tumor induction (9) . More recently, a gene (MNT) was identified that causes feedback inhibition of the Several transcription factors seem to be able to cause cell cycle arrest and, in particular, the group of basic helix-loop-helix (HLH) factors, which induce muscle differentiation and cause growth arrest long before induction of muscle proteins. Careful analysis of the region involved in cell cycle arrest suggests that the HLH region by itself can cause cell cycle arrest, even without the basic region (13) . Other transcription factors, such as the MAD genes, seem to compete with myc to impose arrest (1 1). In addition, several tumor suppressor genes might directly activate transcription, thereby inducing growth arrest, such as the p53 gene, the classical tumor suppressor gene, which appears to be mutated in 50% of all human tumors (14) . p53 activates transcription of p21, a cyclin kinase inhibitor, thereby arresting the cells late in GI before the S phase. p53 can also induce apoptosis through a more elaborate pathway, but mutants have been isolated that can cause growth arrest without subsequent apoptosis (1 5). In fact, in a few cases, p53 controls growth arrest induced by a membrane protein without the participation of the transcription activation domain (16) , which suggests that p53 can interact with other molecules inside the cell remote from the transcription machinery.
Recently it has been established that the p53 gene might need additional factors for maximum stimulation of growth arrest or induction of p21, like the p33ING gene (17) , which appears to bind to p53 to achieve optimal effects. Among the Myc-interacting proteins, a new gene called BIN1 has recently been isolated (18) ity. The suggestion that all these genes are important ingredients in a checkpoint arrest has been borne out by numerous experiments with knockouts in the p53 and the INK4 loci. Likewise, another CDK inhibitor, p21, also seems to work at this stage. This inhibitor is transcriptionally controlled by p53 and accumulates at the checkpoint. The knockout mice lacking p21 undergo normal development but cultivated fibroblasts are only defective in the GI checkpoint (25) .
More recently, it has been demonstrated that the p21 kinase inhibitor can control both the GI/S checkpoint and a checkpoint between G2 and mitosis (G2/M) during cell cycle transition (26) . The latter arrest appears to be independent of Rb and p53 as well as the binding to the proliferating-cell nuclear antigen (PCNA) that has been associated with the GI/S checkpoint. Yet another kinase inhibitor, p27, which lacks a PCNA binding domain, can produce both the GlIS and the G2/M block (26) . It appears that this checkpoint may be mediated through binding to cyclin A-or B1-CDK complexes (27) .
In retrospect, it appears that most of the isolated so-called tumor suppressors operate at the GI/S checkpoint, controlling damaged DNA or stability of the genome before the cells enter into the S phase. Another checkpoint at the G2/M border was only recently identified.
Apoptosis
Programmed cell death, a term originally coined already in 1842, was rediscovered in the second half of this century and referred to as apoptosis in 1972. There are three major findings that have led to the conclusion that cell death is an active process under genetic control. First studies with a small nematode identified a number of genes regulating apoptosis (reviewed in ref. 28 ). Many of them have mammalian homologues that regulate cell death. The signal transduction pathway of apoptosis has identified specific death-signaling molecules, including a completely new family of cysteine proteases, the caspases. Many diseases in humans appear to be due to deficient regulation of the apoptotic program, and in mammalian cells there is a family of receptors, ligands, and signaling molecules that mediate apoptosis in specific cells. In the nematode, essentially three genes, ced-3, ced-4, and ced-9, are directly involved in executing apoptosis during development. Several other genes that also affect apoptotic death are required for recognition of apoptotic cells by the phagocytes, and in some cases, specific genes such as ces-1 and ces-2 can activate the cell death pathway in individual cells. All of the genes that were originally found in the nematodes have their counterpart in mammals: ced-3 corresponds to the caspase-3-like caspases; ced-4 corresponds to Apaf-1, and the regulator ced-9, which can turn off or turn on apoptosis, corresponds to a number of inhibitors and promoters such as Bcl-2 and Bax, respectively (29 
Conclusions
This overview has attempted to point to a deficiency in our accumulated knowledge about the control of the cell cycle exit occurring during development, differentiation, and growth arrest. The main reason for the lack of accumulated data is that we have focused on the induction pathway in cell growth and only recently identified some of the molecular players in checkpoint arrest before transition into the S phase. At this stage, the cell must control radiation damage and DNA stability before it can transverse the border. Most of the growth arrest in the human body probably occurs earlier in the GI state corresponding to the quiescent state (GO), which also precedes some of the differentiation pathways. A much more elaborate approach must therefore be applied to identify the true growth inhibitors in the quiescent state and the interplay that keeps the cells from escaping this control, causing cancer or other diseases. The apoptosis pathway delineated during the last 10 years has clearly shown that apoptosis might occur at the level of the G1/S checkpoint but not necessarily in the GO quiescent state prevailing in the organs in the body. Although apoptosis appears to be an important cell turnover mechanism, we must enhance the screen for genes controlling the expression in truly quiescent cells both in vivo and in vitro.
